Showing 511-520 of 9295 results for "".
Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal reNext Generation Environmental Protection: Antioxidants and Chelators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/next-generation-environmental-protection-antioxidants-and-chelators/23802/As understanding of the pathogenesis of skin aging and carcinogenesis evolves, so do topical protective strategies.The Microbiome in Atopic Dermatitis: Where Are We Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-in-atopic-dermatitis-where-are-we-now/23746/It seems increasingly likely that microbes will play a central role in understanding AD and its treatments.The Dermatology and Aesthetics Market: Continued Mergers and Acquisitions Momentum and Emerging Trends
https://practicaldermatology.com/topics/practice-management/the-dermatology-and-aesthetics-market-continued-mergers-and-acquisitions-momentum-and-emerging-trends/23679/The resilience of the dermatology and aesthetics market, coupled with growth opportunities, continues to fuel the M&A trend.Update on the Treatment of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/update-on-the-treatment-of-actinic-keratoses/21630/From mainstay therapies to newly approved agents, treatment options for actinic keratoses are growing.Upadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.Study Highlights Top-Rated Dermatology Education Apps
https://practicaldermatology.com/topics/practice-management/study-highlights-top-rated-dermatology-education-apps/23565/Researchers rated apps based on four key features.Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.